EP Patent

EP1682564A1 — METHODS FOR PREPARING 7-(2 -SUBSTITUTED-s-D-RIBOFURANO SYL)-4-(NR2R3)-5-(SUBSTITUTED ETHYN-1-YL)-PYRROLO 2,3-D|PYRIMIDINE DERIVATIVES

Assigned to Genelabs Technologies Inc · Expires 2006-07-26 · 20y expired

What this patent protects

Disclosed are methods and intermediates for the preparation of 7-(2'-R1-substituted-ß-D-ribofuranosyl)-4-amino-5-(optionally substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine compounds. These compounds are useful in treating viral infections caused by a flaviviridae family virus, …

USPTO Abstract

Disclosed are methods and intermediates for the preparation of 7-(2'-R1-substituted-ß-D-ribofuranosyl)-4-amino-5-(optionally substituted ethyn-1-yl)-pyrrolo[2,3-d]pyrimidine compounds. These compounds are useful in treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus.

Drugs covered by this patent

Patent Metadata

Patent number
EP1682564A1
Jurisdiction
EP
Classification
Expires
2006-07-26
Drug substance claim
No
Drug product claim
No
Assignee
Genelabs Technologies Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.